AN UPDATE TREATMENT OF ERITEMA NODOSUM LEPROSUM
DOI:
https://doi.org/10.53555/nnmhs.v9i5.1665Keywords:
Eritema Nodosum Leprosum, Leprody, Morbus Hansen, Mycobacterium LepraeAbstract
Leprosy, also called Morbus Hansen, is a contagious skin disease caused by the bacterium Mycobacterium Leprae. It takes 2–5 years for the disease to show up, and it takes 2–3 weeks for the cells to divide. Leprosy reaction is a sudden event that happens during the long-term course of the disease. It causes skin sores to become very red and swollen. This disease can show up before, during, or after treatment for leprosy, and it can happen to 30–50% of people with leprosy. Reactions to leprosy happen when both cellular and humoral immune responses go wrong. Type 2 or Eritema Nodosum Leprosum (ENL) reactions have a clinical picture of the appearance of nodules in the skin. This reaction occurs in leprosy patients with very large numbers of bacteria, namely the multibacillary type. In contrast to the reversal reaction, the humoral immune response plays an important role in the pathogenesis of ENL. Large amounts of bacterial antigen concentrations in tissues will increase IgM and IgG titers in multibacillary leprosy patients. Th2 cell activation will stimulate the production of IL-4 and IL-10, thereby increasing the humoral immune response and increasing the production of B lymphocytes. The goals of the treatment are to control the inflammation, ease the pain, and stop new cases from happening. In weak cases of ENL, the best way to treat it is to rest and take anti-inflammatory drugs. Most of the time, people take aspirin, which is an anti-inflammatory drug. Other drugs have also been tried, including nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, oral zinc, pentoxifylline, and chloroquine. But each of the current treatment options has its own downsides and limitations, and the best one must be carefully chosen for each case.
References
White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015;28(1):80-94.
Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19(2):338-381. doi:10.1128/CMR.19.2.338-381.2006
Han XY, Sizer KC, Thompson EJ, et al. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol. 2009;191(19):6067-6074. doi:10.1128/JB.00762-09
Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature. 2001;409(6823):10071011. doi:10.1038/35059006
Eiglmeier K, Parkhill J, Honoré N, et al. The decaying genome of Mycobacterium leprae. Lepr Rev. 2001;72(4):387-398.
mondiale de la Santé O, Organization WH. Global leprosy update, 2015: time for action, accountability and inclusion. Wkly Epidemiol Rec Relev épidémiologique Hebd. 2016;91(35):405-416.
Chen K-H, Lin C-Y, Su S-B, Chen K-T. Leprosy: A review of epidemiology, clinical diagnosis, and management. J Trop Med. 2022;2022.
James W, Berger T, Elston D. Andrews’ Disease of the Skin, Clinical Dermatology. Elsevier Health Sciences; 2015.
Worobec SM. Treatment of leprosy/Hansen’s disease in the early 21st century. Dermatol Ther. 2009;22(6). doi:10.1111/j.1529-8019.2009.01274.x
Veit O. Manson’s tropical diseases 23rd edition. Travel Med Infect Dis. 2015;13(1). doi:10.1016/j.tmaid.2014.
012
Lastória JC, Abreu MAMM de. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects - part
An Bras Dermatol. 2014;89(2):205-218. doi:10.1590/abd1806-4841.20142450
Mungroo MR, Khan NA, Siddiqui R. Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options. Microb Pathog. 2020;149:104475.
Fava VM, Dallmann-Sauer M, Schurr E. Genetics of leprosy: today and beyond. Hum Genet. 2020;139:835-846.
Mi Z, Liu H, Zhang F. Advances in the immunology and genetics of leprosy. Front Immunol. 2020;11:567.
Handoko R, Djuanda A, Hamzah M, Handoko RP; Djuanda A; Hamzah M; et al. Ilmu Penyakit Kulit Dan Kelamin. 7th ed. Balai Penerbit FKUI; 2017.
Kahawita IP, Walker SL, Lockwood DNJ. Leprosy type 1 reactions and erythema nodosum leprosum. An Bras Dermatol. 2008;83(1). doi:10.1590/S0365-05962008000100010
Sanghi S. IAL Textbook of Leprosy. Med J Armed Forces India. 2010;66(3). doi:10.1016/s0377-1237(10)80066-8
Motta ACF, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K, Foss NT. Leprosy reactions: Coinfections as a possible risk factor. Clinics. 2012;67(10). doi:10.6061/clinics/2012(10)05
Lor KW, Kransdorf EP, Patel JK, Chang DH, Kobashigawa JA, Kittleson MM. Dapsone-Associated Anemia in Heart Transplant Recipients with Normal Glucose-6-Phosphate Dehydrogenase Activity. J Clin Med. 2022;11(21) :6378.
Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. 2014;71(4). doi:10.1016/j.jaad.2014.03.034
Fitzpatrick TB, Wolff K, Goldsmith LA, et al. Fitzpatrick’s Dermatology in General Medicine [Electronic Resource]; 2008.
James WD, Elston DM, Treat JR, Rosenbach MA, Neuhaus IM, Wu Q. Andrews’ Diseases of the Skin, 13th Edition.; 2019.
Bhat RM, Vaidya TP. What is New in the Pathogenesis and Management of Erythema Nodosum Leprosum. Indian Dermatol Online J. 2020;11(4):482-492. doi:10.4103/idoj.IDOJ_561_19
Burns DA, Breathnach SM, Cox NH, Griffiths CEM. Rook’s Textbook of Dermatology: Eighth Edition. Vol 1.; 2010. doi:10.1002/9781444317633
Arora M, Katoch K, Natrajan M, Kamal R, Yadav VS. Changing profile of disease in leprosy patients diagnosed in a tertiary care centre during years 1995-2000. Indian J Lepr. 2008;80(3):257-265.
Balagon MVF, Gelber RH, Abalos RM, Cellona R V. Reactions following completion of 1 and 2 year multidrug therapy (MDT). Am J Trop Med Hyg. 2010;83(3):637-644. doi:10.4269/ajtmh.2010.09-0586
Wankhade VH, Debnath P, Singh RP, Sawatkar G, Bhat DM. A retrospective study of the severe and uncommon variants of erythema nodosum leprosum at a tertiary health center in central India. Int J mycobacteriology. 2019;8(1):29-34. doi:10.4103/ijmy.ijmy_174_18
Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr other Mycobact Dis Off organ Int Lepr Assoc. 2004;72(2):125-133. doi:10.1489/1544-581X (2004)072<0125:ECOLRY>2.0.CO;2
Kaplan G. Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions. Lepr Rev. 2000;71 Suppl:S117-20. doi:10.5935/0305-7518.20000082
Van Veen NHJ, Lockwood DNJ, Van Brakel WH, Ramirez JJ, Richardus JH. Interventions for erythema nodosum leprosum. A Cochrane review. Lepr Rev. 2009;80(4):355-372.
Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2011;52(5):e133-5. doi:10.1093/cid/ciq213
Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337352. doi:10.1111/bph.12139
Narang T, Kaushik A, Dogra S. Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. Br J Dermatol. 2020;182(4):1034-1037. doi:10.1111/bjd.18233
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
